Metformin: the updated protective property in kidney disease

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Metformin is a primary treatment for type 2 diabetes, particularly in obese patients.
• Growing evidence indicates metformin's renoprotective properties against diverse kidney diseases.
• Kidney disease is increasingly viewed as a metabolic disorder involving oxidative stress, inflammation, and impaired cellular defense pathways like AMPK signaling and autophagy.

Purpose of the Study:

• To review the molecular mechanisms underlying metformin's renal protection.
• To explore metformin's therapeutic potential in managing various kidney diseases.

Main Methods:

• Literature review focusing on molecular pathways.
• Analysis of metformin's effects on AMPK signaling and independent pathways.
• Examination of studies investigating metformin in kidney disease models and patient data.

Main Results:

• Metformin modulates key pathophysiologic pathways implicated in kidney disease, including oxidative stress, inflammation, and fibrosis.
• Activation of AMP-activated protein kinase (AMPK) signaling and autophagy are central to metformin's protective effects.
• Metformin also exerts benefits through AMPK-independent mechanisms.
• FDA approval in 2016 for patients with mild/moderate kidney impairment has expanded research scope.

Conclusions:

• Metformin offers significant renal protection through multifaceted molecular actions.
• Its established safety profile and broad efficacy suggest a promising role in treating a spectrum of kidney diseases.